Frankfurt, May 2014. CFP BioConnect – now ACXIT Capital Partners – acted as exclusive financial advisor to Artes Biotechnology GmbH, based in Langenfeld/Germany, on a strategic collaboration with Sun Pharmaceutical Industries, a multinational specialty pharmaceutical company with a diversified product portfolio, headquartered in Mumbai, India.
Artes Biotechnology owns proprietary technology platforms for recombinant proteins and vaccines. Several biopharmaceutical products and industrial enzymes have been successfully introduced to the international markets by its clients and licensees. Under the agreement with Sun Pharmaceutical Industries, Artes Biotechnology will develop cell lines and production processes for several pharmaceutical targets. Sun Pharmaceutical Industries will become a minority shareholder of Artes Biotechnology.
We are particularly proud to execute a transaction involving such a powerful pharma-ceutical company as Sun, the largest Indian pharmaceutical company by means of market capitalisation. It further demonstrates our ability to successfully complete M&A transactions with non-European companies and documents our international reach.
Established in 1983, listed since 1994 and headquartered in India, Sun Pharmaceutical Industries Ltd. is an international specialty pharmaceutical company with over 70% sales from global markets. It manufactures and markets a large basket of pharmaceutical formulations both as branded generics and as generics in US, India and several other markets across the world. For the year ending March 2013, overall revenues were at US$2.1 billion, of which US contributed US$1.1 billion. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, nephrology, gastroenterology, orthopaedics and ophthalmology. The company has strong skills in product development, process chemistry and manufacturing of complex dosage forms. (sunpharma.com)
ARTES is a Germany-based biotechnology company specialized in recombinant protein production and process development from microbial expression systems. ARTES offers generation of optimized production cell lines in proprietary yeast expression systems based on Hansenula polymorpha. In addition to genetic engineering, the company provides fermentation and downstream process development, analytical assay development and production cell line characterization. ARTES operates worldwide from its 850 sqm S1 facilities in Langenfeld. The company focuses on contract R&D for red and white biotechnology products. (artes-biotechnology.com)
ACXIT Capital Partners is a leading international corporate finance and investment advisory firm for mid-market clients and entrepreneurs in Europe and beyond. Since 1998, we offer our clients comprehensive corporate finance advisory services including M&A and capital markets advisory as well as restructuring, debt and strategic advisory. As an independent, privately owned firm we maintain offices in Frankfurt, Berlin, Munich, Zurich, Vienna and Hong Kong as well as strong alliances in China, India and the USA.
To date, we have completed more than 350 transactions with a total deal/financing volume of approx. EUR 17bn. Our clients are corporations, family-owned businesses, entrepreneurs, financial sponsors and family offices. While our home market is in the German speaking region, most clients are international and transactions cross-border. (www.acxit.com)
ACXIT Capital Holding GmbH
Siesmayer Carrée
Siesmayerstraße 21
60323 Frankfurt am Main
Germany
www.acxit.com
facebook.com/acxitcapital
twitter.com/acxitcapital
xing.com/companies/acxitcapitalpartners
linkedin.com/company/acxit-capital-partners
E-mail: press@acxit.com
Dr. Ingmar Ackermann, Managing Partner
E-mail: Ackermann@acxit.com
